In 2024, Merck announced the initiation of the Phase 2/3 REJOICE-Ovarian01 trial evaluating raludotatug deruxtecan (R-DXd), an investigational potential first-in-class CDH6 directed DXd antibody ...

Atea Pharmaceuticals announced the ongoing enrollment in its Phase 3 C-BEYOND trial evaluating the combination of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV).

FOSTER CITY, Calif., May 07, 2025--(BUSINESS WIRE)--Gilead Sciences Inc. (Nasdaq: GILD) today announced final results from the pivotal Phase 3 MYR301 study revealing that 36% (23 out of 64 ...

The phase 3 OVATION 3 trial will evaluate IMNN-001's efficacy and safety ... The IL-12 protein, the company stated, is one of the most active cytokines for the induction of potent anticancer immunity ...

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq: INCY) today announced positive topline results from its pivotal Phase 3 STOP-HS clinical trial program evaluating the safety and efficacy of ...

The abstracts will be published in a supplement of the American Journal of Respiratory and Critical Care Medicine on May 1, 2025. For more details about the ATS International Conference please visit ...

High-performance BMW M versions of both the gas-powered 3-Series and electric i3 are also in the pipeline. The latter is expected to have a four-motor powertrain delivering over 1,000 hp.

Investigators now have data from a phase 3 trial with clazakizumab. The findings from the Phase 3 IMAGINE trial, the largest placebo-controlled study in kidney transplant recipients with caAMR ...

The double-blind, randomized, placebo-controlled phase 3 FIBRONEER-IPF trial achieved its primary endpoint. Boehringer Ingelheim expects to present full findings in the first 6 months of 2025.